Drugs that contain Ulipristal Acetate

1. List of Ella drug patents

ELLA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9844510 LAB HRA PHARMA Ulipristal acetate tablets
Dec, 2028

(5 years from now)

US8735380 LAB HRA PHARMA Ulipristal acetate tablets
Feb, 2029

(5 years from now)

US10772897 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(6 years from now)

US9283233 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(6 years from now)

US10159681 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(6 years from now)

US8512745 LAB HRA PHARMA Ulipristal acetate tablets
Jun, 2030

(7 years from now)

US8426392 LAB HRA PHARMA Method for providing emergency contraception
Jun, 2030

(7 years from now)

US8962603 LAB HRA PHARMA Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
Jun, 2030

(7 years from now)

Do you want to check out ELLA patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Jun 24, 2024

Market Authorisation Date: 13 August, 2010

Treatment: A method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse; Method for contra...

Dosage: TABLET;ORAL

How can I launch a generic of ELLA before it's patent expiration?
More Information on Dosage

ELLA family patents

18

United States

8

European Union

4

Japan

3

China

3

New Zealand

2

Spain

2

Hong Kong

2

Denmark

2

RS

2

Poland

2

Russia

2

Canada

2

San Marino

2

Croatia

2

Cyprus

2

Portugal

2

Australia

2

South Africa

2

Lithuania

2

Slovenia

2

Hungary

1

Brazil

1

Ukraine

1

ME

1

Korea, Republic of

1

Israel

1

Mexico

1

Colombia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic